AI Article Synopsis
- Hepatitis B (HBV) and C (HCV) are major global causes of liver disease, leading to liver fibrosis, but there’s limited understanding about how well different diagnostic tools like APRI and FIB-4 compare to fibroscan in diagnosing this condition.
- The study assessed liver damage in 185 patients (82 with HBV and 103 with HCV) using APRI, FIB-4, and fibroscan, finding that while APRI and FIB-4 indicators were effective for predicting cirrhosis, they were less reliable for lower-grade fibrosis.
- Results indicated that fibroscan is superior to both APRI and FIB-4 in predicting liver
Article Abstract
Background: Hepatitis B (HBV) and hepatitis C viruses (HCV) are significant causes of liver disease worldwide. Liver fibrosis (LF) is a complication of chronic liver damage caused by HBV and HCV due to our limited knowledge comparing the diagnostic performance of platelet to aspartate aminotransferase ratio index (APRI) and fibrosis-4 (FIB-4) index with fibroscan.
Methods: This study evaluated liver damage in HBV and HCV using APRI, FIB-4, and fibroscan indices. This retrospective cohort descriptive-analytical study was conducted on patients with HBV and HCV. This study uses laboratory results and imaging to investigate liver damage in chronic HBV and HCV patients. APRI and FIB-4 were computed based on laboratory results.
Results: A total of 185 patients (82 hepatitis B and 103 hepatitis C) were included in the study. Thirteen patients had liver cirrhosis. There was no statistically significant difference between the fibroscan results in the two groups (=0.99). The HBV group's mean APRI and FIB-4 were lower than HCV, but no significant difference was observed (>0.05). Our results in HBV and HCV patients showed that APRI and FIB-4 accomplished well anticipating cirrhosis with an area under the receiver operating characteristic curve (AUC) of 0.771-0.845 and 0.871-0.910, respectively.
Conclusion: Fibroscan is a powerful tool superior to APRI and FIB-4 in predicting LF and cirrhosis. Nevertheless, APRI and FIB-4 are inexpensive and non-invasive indicators with acceptable efficacy in predicting advanced fibrosis or cirrhosis. However, these two measures are not reliable in low-grade fibrosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230742 | PMC |
| http://dx.doi.org/10.1097/MS9.0000000000002095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of the Fibrosis Score and the Child-Turcotte-Pugh (CTP) Score in Patients With Chronic Liver Disease in India.
Cureus
November 2024
Department of Medicine, Baba Raghav Das Medical College, Gorakhpur, Gorakhpur, IND.
Objective: This study aimed to evaluate the severity of liver fibrosis in chronic liver disease patients using aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 (FIB-4), FibroScan, and the Child-Turcotte-Pugh (CTP) score. It emphasized assessing fibrosis progression toward cirrhosis (F4 stage) and exploring the correlation between non-invasive markers and the CTP score for liver function and prognosis.
Methodology: This observational cross-sectional study was conducted over one calendar year in the Department of Medicine at Baba Raghav Das (BRD) Medical College, Gorakhpur, India.
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia.
Clin Exp Hepatol
September 2024
Hatanodai Hospital, Japan.
Aim Of The Study: Non-alcoholic fatty liver disease (NAFLD) is a pathological condition associated with inflammation owing to fat deposition in the liver. Managing hypertriglyceridemia is essential for patients with NAFLD, including treatment with pemafibrate. However, whether pemafibrate affects fat deposition in the liver and whether hypertriglyceridemia is the primary treatment target remain unclear.
View Article and Find Full Text PDFAssessment of the Child-Pugh Score, Model for End-Stage Liver Disease Score, Fibrosis-4 Index, and AST to Platelet Ratio Index as Non-endoscopic Predictors of the Presence of Esophageal Varices and Variceal Bleeding in Chronic Liver Disease Patients.
Cureus
November 2024
Gastroenterology and Hepatology, Osmania General Hospital, Hyderabad, IND.
Background Esophageal varices (EVs) develop as a complication of chronic liver disease and, when left unaddressed, can lead to variceal hemorrhage manifesting as severe hematemesis and occasionally, melena. Due to its frequent negative associations, early diagnosis and the implementation of non-selective beta blocker primary prophylaxis are imperative. Although upper gastrointestinal endoscopy has historically been used to image and identify EVs, patients frequently find this intrusive treatment to be uncomfortable and burdensome.
View Article and Find Full Text PDFFully automated MRI-based convolutional neural network for noninvasive diagnosis of cirrhosis.
Insights Imaging
December 2024
Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Objectives: To develop and externally validate a fully automated diagnostic convolutional neural network (CNN) model for cirrhosis based on liver MRI and serum biomarkers.
Methods: This multicenter retrospective study included consecutive patients receiving pathological evaluation of liver fibrosis stage and contrast-enhanced liver MRI between March 2010 and January 2024. On the training dataset, an MRI-based CNN model was constructed for cirrhosis against pathology, and then a combined model was developed integrating the CNN model and serum biomarkers.
Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China.
Front Med (Lausanne)
November 2024
Liver Diseases Center, Ningbo No. 2 Hospital, Ningbo, China.
Background: Over the past decade, the proportion of hepatitis C virus (HCV) genotypes (GT) 1 and 2 has decreased in almost all regions of China, while GT 3 and 6 have emerged as new challenges. GT 6 is unique in many respects, like high genetic variability and emerging resistant variants. This study aims to assess the efficacy of sofosbuvir (SOF)-based treatments in patients with GT 6 chronic hepatitis C (CHC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!